UnitedHealth Group shares reached a 52-week high in the trading session after its strong second-quarter earnings report, then eased back. The stock has recently traded around $390, still within a 52-week range of $255.97 to $461.62, according to CNN and Seeking Alpha market data. The earnings strength comes alongside a federal investigation into the company’s billing practices and a new shareholder lawsuit alleging governance and cybersecurity failures tied to the 2022 Change Healthcare data breach; both matters remain unresolved.
Key facts
- Stock price: recently around $390, within a 52-week range of $255.97 to $461.62
- Q2 2026 revenue: $112.0 billion, up from $111.6 billion a year earlier
- Adjusted EPS: $6.38, beating the roughly $4.90 Wall Street had expected
- Medical care ratio: 86.7%, down from 89.4% a year earlier
- 2026 guidance: raised to $19.50–$20.00 per share, up from more than $18.25
- Quarterly dividend: $2.32 per share, payable September 22 to shareholders of record September 14
- DOJ investigation: civil probe into Medicare Advantage billing practices; a parallel criminal inquiry has been reported; no charges filed
- New lawsuit: filed August 7 over UnitedHealth’s 2022 Change Healthcare data breach
A big earnings beat, and raised guidance
UnitedHealth reported its second-quarter 2026 results on July 16. Revenue came in at $112.0 billion, up from $111.6 billion a year earlier, and adjusted earnings per share hit $6.38 — well above the roughly $4.90 Wall Street had expected, according to CNBC and the company’s own SEC filing. The quarter also generated $11.1 billion in operating cash flow, and the medical care ratio benefited from $860 million in net favorable prior-period medical reserve development. Earnings from operations rose year over year to $8.0 billion from $5.2 billion, with both the UnitedHealthcare insurance business and the Optum health-services arm contributing. Optum reported $65.7 billion in revenue and $4.0 billion in operating earnings for the quarter.
A key number behind that swing was the medical care ratio — the share of premium revenue the company pays out in medical claims — which fell to 86.7% from 89.4% a year earlier. A lower ratio is good news for an insurer’s bottom line: it means UnitedHealth kept more of every premium dollar than it did in 2025. On the strength of those results, the company raised its full-year 2026 adjusted earnings guidance to a range of $19.50 to $20.00 per share, up from a prior outlook of more than $18.25, and improved its full-year medical care ratio outlook to 88.1% ± 0.25 percentage points from 88.8% ± 0.50 percentage points, with operating cash flow guidance of approximately $24 billion.
Shares touched a 52-week high of $461.62 in the trading session that followed the earnings release, per Yahoo Finance and TipRanks, before easing back into the high-$300s and $390s range where they have traded in more recent sessions around August 21 through 23.
On Wall Street, analyst reaction has been mixed but generally positive, according to reporting from TipRanks:
- Morgan Stanley: price target raised to $411, up from $395; kept an “Overweight” rating
- Bank of America: price target raised to $390, up from $350; kept a more cautious “Neutral” rating
UnitedHealth’s board also authorized a quarterly cash dividend of $2.32 per share on August 12, according to Yahoo Finance. It’s payable September 22 to shareholders of record as of September 14. The same day, UnitedHealthcare announced it was expanding access to child and family behavioral coaching to 13 million commercial members. No reporting has tied the DOJ investigation, the earnings results or the new lawsuit to any change in premiums, coverage or how claims are handled for current UnitedHealth members.
A federal investigation that hasn’t produced charges
The earnings strength sits alongside a Department of Justice investigation the company has publicly acknowledged. UnitedHealth confirmed in an SEC filing that it faces a civil Department of Justice investigation into whether it added high-value diagnoses to patients’ records to raise the risk scores Medicare Advantage uses to calculate payments — a matter that first surfaced in mid-2025. The company says it proactively contacted the DOJ and has launched its own third-party review of billing practices. Separate reporting that cites the Wall Street Journal describes a parallel criminal inquiry, which it says is expanding to include billing at Optum Rx, the company’s pharmacy-benefits unit, and how UnitedHealth reimburses its own physicians. No charges, fine or settlement in the matter has been confirmed, and there is no indication yet of a timeline for when the investigation might conclude or what, if anything, it could lead to.
A new lawsuit over the Change Healthcare breach
This is the new lawsuit driving part of this week’s coverage — separate from an earlier, still-pending suit described below. An amended shareholder complaint was filed August 7 in federal court in Minnesota. The plaintiffs include Rhode Island’s public employee retirement system and Swedish asset manager Länsförsäkringar Fondförvaltning AB, which reporting says owns more than $123 million in UnitedHealth stock. They allege that the company’s board ignored governance and cybersecurity oversight risks for years leading up to its 2022 acquisition of Change Healthcare, which later suffered what the suit calls the largest healthcare data breach on record in the United States. The complaint also alleges that CEO and board chairman Stephen Hemsley supported eliminating an internal Medicare-billing audit program that had found UnitedHealth submitted at least $200 million in unsupportable Medicare diagnosis codes.
It’s a separate matter from an earlier, still-pending suit filed in March 2026 by a faith-based investor coalition after UnitedHealth moved to exclude a shareholder proposal seeking disclosure of the healthcare impacts of its acquisition and vertical-integration strategy in the company’s 2026 proxy materials.
The Mangione case: a separate story in the same headlines
One more thread has been drawing search interest in UnitedHealth this week, though it isn’t a financial or business development. Luigi Mangione is accused of killing Brian Thompson — who led the UnitedHealthcare insurance subsidiary, not UnitedHealth Group as a whole — in December 2024. On August 14, Mangione pleaded guilty in Manhattan federal court to two federal stalking counts tied to tracking Thompson before the killing; his federal sentencing has been scheduled for December 18, 2026. Public search interest in UnitedHealth rose alongside the plea, but no reporting has tied it to the stock’s price — the earnings, guidance, DOJ investigation and shareholder lawsuit described above are separate matters. UnitedHealth’s current CEO is Stephen Hemsley, who returned to the role in May 2025 — his second stint leading the company, having previously served as CEO from 2006 to 2017 — after Andrew Witty stepped down.
Timeline
- 2022 — UnitedHealth acquires Change Healthcare, which later suffers what the lawsuit calls the largest healthcare data breach on record in the U.S.
- December 2024 — Brian Thompson, who led UnitedHealthcare, is killed; Luigi Mangione is accused
- Mid-2025 — The DOJ’s Medicare Advantage billing investigation first surfaces
- March 2026 — An earlier, still-pending shareholder suit is filed by a faith-based investor coalition
- July 16, 2026 — UnitedHealth reports Q2 2026 earnings, beats estimates, raises full-year guidance
- August 7, 2026 — Amended shareholder lawsuit over the Change Healthcare breach is filed in Minnesota federal court
- August 12, 2026 — Board authorizes a $2.32/share quarterly dividend; UnitedHealthcare expands behavioral coaching access
- August 14, 2026 — Mangione pleads guilty to two federal stalking counts
- September 14, 2026 — Dividend record date
- September 22, 2026 — Dividend payable
- December 18, 2026 — Mangione’s federal sentencing scheduled
Where things stand
UnitedHealth has had several major developments in recent weeks: a Q2 earnings beat, raised full-year guidance, a dividend authorization, DOJ scrutiny and a new shareholder lawsuit. For now, the raised guidance and improved medical care ratio are the clearest confirmed changes in the company’s operating outlook; the legal and regulatory questions remain open, and neither the DOJ investigation nor the shareholder lawsuit has reached a resolution.